Back to Search Start Over

Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives.

Authors :
Tanas AS
Sigin VO
Kalinkin AI
Litviakov NV
Slonimskaya EM
Ibragimova MK
Ignatova EO
Simonova OA
Kuznetsova EB
Kekeeva TV
Larin SS
Poddubskaya EV
Trotsenko ID
Rudenko VV
Karandasheva KO
Petrova KD
Tsyganov MM
Deryusheva IV
Kazantseva PV
Doroshenko AV
Tarabanovskaya NA
Chesnokova GG
Sekacheva MI
Nemtsova MV
Izhevskaya VL
Kutsev SI
Zaletaev DV
Strelnikov VV
Source :
Epigenomics [Epigenomics] 2019 May; Vol. 11 (6), pp. 605-617. Date of Electronic Publication: 2019 Feb 07.
Publication Year :
2019

Abstract

Aim: To provide a breast cancer (BC) methylotype classification by genome-wide CpG islands bisulfite DNA sequencing. Materials & methods: XmaI-reduced representation bisulfite sequencing DNA methylation sequencing method was used to profile DNA methylation of 110 BC samples and 6 normal breast samples. Intrinsic DNA methylation BC subtypes were elicited by unsupervised hierarchical cluster analysis, and cluster-specific differentially methylated genes were identified. Results & conclusion: Overall, six distinct BC methylotypes were identified. BC cell lines constitute a separate group extremely highly methylated at the CpG islands. In turn, primary BC samples segregate into two major subtypes, highly and moderately methylated. Highly and moderately methylated superclusters, each incorporate three distinct epigenomic BC clusters with specific features, suggesting novel perspectives for personalized therapy.

Details

Language :
English
ISSN :
1750-192X
Volume :
11
Issue :
6
Database :
MEDLINE
Journal :
Epigenomics
Publication Type :
Academic Journal
Accession number :
30729807
Full Text :
https://doi.org/10.2217/epi-2018-0213